complication of aminoglycosides, which is mostly associated with acute renal failure, has been documented Background. The use of aminoglycosides has been linked with hypomagnesaemia in scattered reports. The in scattered anecdotal reports [1] [2] [3] [4] [5] . Recent observations in animals indicate the frequent occurrence of objective of the study was to measure prospectively the effect of treatment with the aminoglycoside renal magnesium wasting even in the absence of both renal failure [6] [7] [8] and abnormalities in renal tubular amikacin on renal magnesium homeostasis. Methods. Twenty-four cystic fibrosis patients (aged morphology [8] .
Introduction
interval since the last hospital treatment of 6 or more months.
Combined anti-pseudomonal treatment with amikacin
Renal magnesium wasting is considered a rare (33 mg/kg daily in three divided doses) and ceftazidime complication of treatment with aminoglycosides. This (250 mg/kg daily in four divided doses) for 14 days was instituted in all patients [13] . The dose of amikacin was
Correspondence and offprint requests to: Dr M. G. Bianchetti, adjusted in the patients to achieve trough plasma concentra- Before and at the end of the 14 days treatment period a The urinary excretion of N-acetyl-b--glucosaminidase (unit, 2-h urine specimen was collected after overnight fasting, U/l ) was factored by creatinine (unit, mmol/l ). An estimate sitting (more than 10 min) blood pressure (first and fifth of aldosterone activity is the potassium concentration gradisounds), and heart rate were measured, and mid-point blood ent between blood and nephron at the end of the cortical was taken anaerobically with minimal stasis and without collecting tubule [18] . To assess the mentioned gradient and movement of the forearm. Haemoglobin, pH, carbon dioxide thereby the aldosterone activity, a non-invasive test has been pressure, urea, albumin, and ionized calcium and magnesium designed. Consequently, the transtubular potassium concenwere assessed in blood, and total magnesium, sodium, potastration gradient was calculated from plasma and urinary sium, chloride, uric acid, phosphate, creatinine and osmolalpotassium (P K , U K ; in mmol/l ) and osmolality (P osm , U osm ; ity in both blood and urine, and total calcium in urine. In in mmol/kg) by the equation [18]: addition urinalysis (glucose and protein) and the excretion of N-acetyl-b--glucosaminidase were assessed.
Plasma and urine were also collected in a control group U K U osm × P osm P K of 25 subjects (11 female and 14 males, aged between 4.1 and 19, median 12 years) with either nocturnal enuresis The results are expressed either as median and interquartile (n=16), dysfunctional voiding (n=5), or unstable bladder range or depicted as 'box and whisker plot' (boxes are (n=4).
median and interquartile ranges, vertical lines are ranges).
The Wilcoxon matched-paired-signed rank test (nonparametric rank sum test for paired samples), the
Data analysis
Wilcoxon-Mann-Whitney test (non-parametric rank sum test for two independent samples), and simple regressions All measurements were performed in duplicate. Haemoglobin with the non-parametric coefficient of correlation r s were (cyanhaemoglobin method ), uric acid (uricase-catalase used for analysis. A P value of <0.05 was accepted as assay), albumin (bromcresol purple method ), total calcium statistically significant. [16 ] were measured colorimetrically. Osmolality was assessed When studied before amikacin and ceftazidime, the by freezing point osmometry, glycosylated haemoglobin A 1c group of 24 patients with cystic fibrosis slightly by a latex immunoagglutination inhibition assay, and circu-but significantly tended towards tachycardia, hypolating amikacin by fluorescence polarization assay. Urinary albuminaemia, hypocalcaemia, and hyperuricaemia glucose and protein were determined using commercially ( Table 1) [11] . The electrode contains the neutral carrier-based ium were similar in 16 cystic fibrosis patients with at membrane ETH 7025, which is incorporated in standard least one treatment course with aminoglycosides in the AVL electrode bodies by solvent casting (AVL 988-4/Mg past and in the eight patients without such a course.
Analyzer). The cell is provided with electrodes for sodium, Systemic treatment with amikacin and ceftazidime, calcium, pH, and magnesium together with a common referintensive physiotherapy, inhalation therapy, and highence electrode. The measuring cell is maintained at 37°C. Plasma or urinary electrolytes (P x , U x ) and creatinine (P Cr , calorie diet did not significantly ameliorate the noted U Cr ) were used to calculate the fractional clearance (1) or tendency towards tachycardia, hypoalbuminaemia, the excretion corrected for 1 litre of glomerular filtration hypocalcaemia and hyperuricaemia (Table 1) . Also rate (GFR) (2), using the following standard equations: blood pressure, body weight, haemoglobin, plasma creatinine and urea, blood acid-base balance, and
(1) plasma and urinary sodium, potassium and phosphate were unchanged following systemic anti-pseudomonal treatment with amikacin and ceftazidime for 14 days. Table 1 . Clinical and laboratory findings in 24 patients (11 female and 13 male, aged between 9.0 and 19 years, median 14) with cystic fibrosis, before and after treatment with amikacin and ceftazidime for 14 days, and in a control group of 25 healthy subjects (11 Consequently the study demonstrates that in cystic tendency towards hypomagnesaemia was associated fibrosis, systemic therapy with the aminoglycoside amiwith a significantly increased fractional magnesium kacin plus the cephalosporin ceftazidime causes mild clearance (from 0.0568 (0.0494-0.0716) to 0.0721 and probably transient [1] [2] [3] [4] [5] hypomagnesaemia sec-(0.0630-0.111)) and urinary magnesium excretion ondary to inappropriate renal magnesium wasting even (from 30.7 (26.5-38.0) to 38.5 (31.5-49.0) mmol/l in the absence of a rise in circulating creatinine and glomerular filtration rate (GFR)). In patients no corurea. relation was observed between the changes in the In cystic fibrosis the drawbacks of hypomagnesaemia urinary excretion of magnesium and those in the on respiratory symptoms have not been addressed. urinary excretion of N-acetyl-b--glucosaminidase.
Data from the literature suggest that in humans, hypomagnesaemia may reduce respiratory muscle power and cause airflow obstruction [22] . Our findings
Discussion
of hypoalbuminaemia, hypocalcaemia, and hyperuricaemia in advanced cystic fibrosis before and at the end When magnesium intake is curtailed or when there is of systemic anti-pseudomonal therapy concur with the intestinal magnesium malabsorption the normal kidney literature [23] [24] [25] [26] . Hypoalbuminaemia and hypocalcareduces magnesium excretion to very low values. When emia reflect the severity of exocrine pancreatic insuffirenal magnesium handling is impaired, hypomagnesae-ciency that leads to malabsorption of fat, fat-soluble mia ensues because, unlike with calcium, equilibration vitamins (such as vitamin D), and protein [23] [24] [25] . On with cellular stores does not occur for several weeks the other hand, hyperuricaemia is secondary to the [9, 10, 19, 20] . In the present study, treatment with ami-purine contamination of the pancreatic replacement kacin plus ceftazidime for 14 days very often caused therapy [26 ] . None of our cystic fibrosis patients was subtle changes in the renal magnesium homeostasis. on treatment with diuretics, the drugs most frequently associated with hyperuricaemia [26 ] . However, the treatment was not associated with phology are detectable [8] . Our data and the literature do not provide information on the nephron site and on the cellular site at which aminoglycosides interfere with the magnesium transport. N-acetyl-b--glucosaminidase is a large lysosomal enzyme that does not undergo glomerular filtration [21, 29] . Since this enzyme is located predominantly within the proximal tubule, an increased excretion is generally interpreted as evidence of proximal tubular injury and has been shown to occur in humans 2-3 days after onset of aminoglycoside therapy [21, 29] . In the experimental animal, however, an increased excretion of this enzyme occurs before the development of histologically detectable tubular injury, suggesting that aminoglycosides simply interfere with the cellular cycling of the enzyme [8] . In the present study the urinary magnesium excretion did not parallel that of N-acetyl-b--glucosaminidase. Furthermore data from the literature indicate that the reabsorption of magnesium predominantly occurs by paracellular diffusion in the thick ascending loop of Henle [19, 20] . Recent studies disclosed the gene encoding paracellin-1, a protein found exclusively in the tight junctions of the thick ascending loop of Henle that mediates the paracellular reabsorption of magnesium and calcium [30] . Available data do not provide information on the possible interaction between aminoglycosides and the paracellular reabsorption of magnesium. Whatever the underlying mechanisms, the In cystic fibrosis some further causes of renal magnesium wasting deserve mention, including intestinal malabsorption, the use of diuretics, diabetes melPseudomonas aeruginosa is a major cause of bronchopulmonary morbidity in cystic fibrosis [13, 14] . litus and aldosteronism [9, 10] . In the present study, however, cystic fibrosis patients on treatment with Aggressive chest physiotherapy, nutritional management, and intravenous antibiotics for 14 days have diuretics or with diabetes mellitus were excluded.
Furthermore, we failed to disclose signs consistent with been largely responsible for the increased life-span of patients with cystic fibrosis. In most centres the stand-aldosteronism, as indicated by the transtubular potassium gradient [18] . These factors probably account for ard antibiotic regimen for acute exacerbation includes a b-lactam (e.g. ceftazidime) and an aminoglycoside the rather mild degree of magnesium deficiency noted in our patients after aminoglycosides. Hence we assume (e.g. amikacin) [13, 14] . Ceftazidime is a recognized anti-pseudomonal agent [27, 28] . No report mentions that aminoglycosides may cause a more severe magnesium deficiency in cystic fibrosis patients with poorly a possible link between ceftazidime or other b-lactams and magnesium wasting. Aminoglycosides are a main-controlled intestinal malabsorption or secondary diabetes mellitus, in those treated with diuretics, or in stay in the management of severe Gram-negative infection but are nephrotoxic [21] . those with aldosteronism. It behoves us to be alert for the possible occurrence of hypomagnesaemia among Acute renal failure is a relatively common complication of aminoglycoside therapy that can occur cystic fibrosis patients so that severely affected subjects can be given replacement. even if drug levels are closely monitored [21] . Aminoglycosides undergo uptake into the proximal Hypokalaemia, hypocalcaemia, or hypophosphataemia sometimes occur in patients with severe hypomtubular cells, accumulate within lysosomes, and cause a histologically detectable damage and renal failure agnesaemia [9, 10] . In the cystic fibrosis patients presented in this study mild renal magnesium wasting was [21] . None of the patients included in this study developed acute renal failure. The results of our study not linked with hypokalaemia. A tendency towards hypocalcaemia, however, was observed both before as concur with those of investigations in rats. In this animal aminoglycosides acutely decrease the tubular well as after treatment with amikacin and ceftazidime.
It is therefore speculated that hypocalcaemia is related reabsorption of magnesium [6] [7] [8] and increase the excretion of N-acetyl-b--glucosaminidase [8] . directly to cystic fibrosis, as discussed above.
It has been known for many years that aminoglycosHowever, glomerular filtration rate remains unaffected [6] [7] [8] and no abnormalities in renal tubular cell mor-ides sometimes cause renal magnesium wasting [1] [2] [3] [4] [5] .
of inhaled amikacin as adjunct to intravenous combination This prospective study indicates that in cystic fibrosis therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr treatment with amikacin plus ceftazidime for 14 days 1987; 111: 599-605 often causes renal magnesium wasting.
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